The IBD Clinic: Continuity of Care in IBD - From Diagnosis to Management

The Gastroenterology Learning Pathway
0.75 AMA PRA Category 1 Credit(s)
Launch Date:
February 02, 2017
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Gastroenterologists and Gastroenterology Clinicians

Relevant Terms:

IBD Management

Adam S. Cheifetz, MD

Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Adam S. Cheifetz, MD, graduated magna cum laude from Brown University before earning his M.D. from Cornell University Medical College. Dr. Cheifetz completed his internship and residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Gastroenterology at Yale University before serving as the Present-Levinson Fellow in Inflammatory Bowel Disease at the Mount Sinai Medical Center in New York City.
Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School. He is Director of the Harvard Medical School Gastroenterology Clerkship Elective and Assistant Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases. For the last eight years, Dr. Cheifetz has been cited in Boston Magazine as one of Boston's Top Doctors. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 100 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies. Dr. Cheifetz lectures nationally and internationally on IBD.  
Dr. Cheifetz is also actively involved with teaching and mentoring medical students, residents, and fellows and is proud to have trained numerous physicians who now specialize in IBD. In addition, he serves on numerous editorial boards including Inflammatory Bowel Diseases, Journal of Clinical Gastroenterology, Journal of Crohn's and Colitis, and the World Journal of Gastroenterology.
Dr. Cheifetz has been involved with the CCFA for over 10 years on both a regional and national level. He is a long-time member of the New England Chapter Medical Advisory Committee and is the immediate past Chairman. He was recently named the NE Chapter CCFA 2015 Humanitarian of the Year. In addition, he serves on the National Scientific Advisory Committee and at this time is Co-Chairman of the CCFA Membership Committee.

Uma Mahadevan, MD

Uma Mahadevan, MD
Professor of Medicine
University of California, San Francisco
Co-Medical Director
UCSF Center for Colitis and Crohn's Disease
San Francisco, CA

Uma Mahadevan, MD, completed a medical degree at the State University of New York in Brooklyn. She completed residency in internal medicine at Mount Sinai Medical Center in New York, a fellowship in gastroenterology at the University of California, San Francisco (UCSF), and a fellowship in inflammatory bowel disease (IBD) at the Mayo Clinic in Rochester, Minnesota. Dr. Mahadevan currently serves as Professor of Medicine at UCSF and Co-Medical Director of the UCSF Center for Colitis and Crohn's Disease and Director of the IBD Fellowship.
Certified by the American Board of Internal Medicine as a diplomate in internal medicine and gastroenterology, Dr. Mahadevan is a fellow of the American Gastroenterological Association, for whom she is a vice-chair for the Clinical Immunology, Microbiology and Inflammatory Bowel Disease (IMIBD) Section and co-director of the 2017 Post-Graduate Course. She is also a fellow of the American College of Gastroenterology for which she is chair of IBD for the 2017 ACG course and a member of the Educational Affairs Committee. She is currently co-chair of the CCFA Clinical Research Grants committee and a member of their National Scientific Advisory Committee.
Dr. Mahadevan is a special section editor for Gastroenterology and an editorial board member and reviewer for several other journals. Dr. Mahadevan has published original articles, abstracts, editorials, and invited reviews in such peer-reviewed journals as Gastroenterology, Gut, American Journal of Gastroenterology and Inflammatory Bowel Diseases along with several book chapters. Dr. Mahadevan specializes in the treatment of ulcerative colitis, Crohn's disease, and pouchitis. She has a particular interest in pregnancy and fertility in IBD, as well as in clinical trials of experimental therapy for both ulcerative colitis and Crohn's disease. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO), clinical trials in biologic therapy for IBD, and microbiome, environmental and dietary changes.

David A. Schwartz, MD, FACG, AGAF

David A. Schwartz, MD, FACG, AGAF
Professor of Medicine
Director, Inflammatory Bowel Disease Center
Vanderbilt University Medical Center
Nashville, TN

David A. Schwartz, MD, is Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University in Nashville, Tennessee. He founded and currently serves as Director of the Inflammatory Bowel Disease Center at Vanderbilt University Medical Center.
Dr. Schwartz received his postgraduate training at the Mayo Clinic in Rochester, Minnesota, where he completed a fellowship in Gastroenterology and Hepatology, and advanced training in Inflammatory Bowel Disease and Endoscopic Ultrasound. He is a Fellow of the American College of Gastroenterology and the American Gastroenterological Association.
Dr. Schwartz's research has focused on clinical trials for inflammatory bowel disease, imaging of inflammatory bowel disease, the multidisciplinary care of the IBD patient, and the treatment of perianal Crohn's disease. He has lectured extensively throughout the United States and has written more than 200 articles, book chapters, and abstracts.

Robin Dalal, MD

Robin Dalal, MD 
Gastroenterology Fellow
Vanderbilt University Medical Center
Nashville, TN

Robin Dalal, MD, graduated from the Medical College of Georgia in Augusta, Georgia, and completed her internal medicine residency at Vanderbilt University Medical Center in Nashville, Tennessee. She served a year as Chief Resident in internal medicine at Vanderbilt prior to starting fellowship in gastroenterology and hepatology.
Dr. Dalal is currently a gastroenterology fellow at Vanderbilt. She has recently accepted a faculty position at Vanderbilt University Medical Center and will start in the summer of 2017.
Dr. Dalal's clinical interest is in inflammatory bowel disease (IBD). She has presented and lectured at multiple meetings, conferences, and events across the country. Dr. Dalal is a member of the Crohn's and Colitis Foundation of America, the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy.
1. Compare and contrast the clinical effects of IBD therapies
2. Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity
3. Utilize available disease progression and drug monitoring strategies for patients with IBD
4. Implement American Gastroenterological Association (AGA) practice measures in managing patients with IBD

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Adam Cheifetz, MD, has affiliations with Consulting: AbbVie, Pfizer, Samsung, Takeda.
  • Uma Mahadevan, MD, has affiliations with Consulting: AbbVie, Celgene, Janssen, Pfizer, Takeda, UCB Pharma; Grant Support: Prometheus Laboratories.
  • David Schwartz, MD, has affiliations with Consulting: AbbVie, Janssen, Takeda, Tigenix, UCB Pharma; Grant Support: AbbVie, UCB Pharma.
  • Robin Dalal, MD, has no affiliations with commercial interests to disclose.
RMEI Medical Education, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests to disclose.
  • Nora Hartley has no affiliations with commercial interests to disclose.
AGA Institute
  • Sandra Megally Amos has no affiliations with commercial interests to disclose.
  • Maura H. Davis has no affiliations with commercial interests to disclose.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 0.75 hours
Medium: Internet

There is no fee for this educational activity.

This activity is supported by independent educational grants from AbbVie, Shire, and Takeda Pharmaceuticals, USA, Inc.

By reviewing the course content and successfully completing the activity, physicians, nurse practitioners, and physician assistants are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the self-assessment questions and evaluation will receive CME credit. You must score 75% or higher on the self-assessment test to receive credit for this activity. All other participants who successfully complete the activity and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above